Cancer Evolution: A Multifaceted Affair

Author:

Ciriello Giovanni12ORCID,Magnani Luca345ORCID,Aitken Sarah J.67ORCID,Akkari Leila8ORCID,Behjati Sam91011ORCID,Hanahan Douglas112ORCID,Landau Dan A.131415ORCID,Lopez-Bigas Nuria161718ORCID,Lupiáñez Darío G.19ORCID,Marine Jean-Christophe2021ORCID,Martin-Villalba Ana22ORCID,Natoli Gioacchino23ORCID,Obenauf Anna C.24ORCID,Oricchio Elisa125ORCID,Scaffidi Paola2326ORCID,Sottoriva Andrea27ORCID,Swarbrick Alexander2829ORCID,Tonon Giovanni3031ORCID,Vanharanta Sakari3233ORCID,Zuber Johannes2434ORCID

Affiliation:

1. 1Swiss Cancer Center Leman, Lausanne, Switzerland.

2. 2Department of Computational Biology, University of Lausanne, Lausanne, Switzerland.

3. 3The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.

4. 4Breast Epigenetic Plasticity and Evolution Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.

5. 5Department of Surgery and Cancer, Imperial College London, London, United Kingdom.

6. 6Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, United Kingdom.

7. 7Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

8. 8Division of Tumor Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

9. 9Wellcome Sanger Institute, Hinxton, United Kingdom.

10. 10Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

11. 11Department of Paediatrics, University of Cambridge, Cambridge, United Kingdom.

12. 12Ludwig Institute for Cancer Research, Lausanne, Switzerland.

13. 13New York Genome Center, New York, New York.

14. 14Division of Hematology and Medical Oncology, Department of Medicine and Meyer Cancer Center, Weill Cornell Medicine, New York, New York.

15. 15Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York.

16. 16Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.

17. 17Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.

18. 18Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

19. 19Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin Institute for Medical Systems Biology, Berlin, Germany.

20. 20Laboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium.

21. 21Laboratory for Molecular Cancer Biology, Department of Oncology, KULeuven, Leuven, Belgium.

22. 22Department of Molecular Neurobiology, German Cancer Research Center (DFKZ), Heidelberg, Germany.

23. 23Department of Experimental Onco­logy, European Institute of Oncology IRCCS, Milan, Italy.

24. 24Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria.

25. 25Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.

26. 26Cancer Epigenetic Laboratory, The Francis Crick Institute, London, United Kingdom.

27. 27Computational Biology Research Centre, Human Technopole, Milan, Italy.

28. 28Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, Australia.

29. 29School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia.

30. 30Vita-Salute San Raffaele University, Milan, Italy.

31. 31Center for Omics Sciences, IRCCS San Raffaele Scientific Institute, Milan, Italy.

32. 32Translational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

33. 33Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

34. 34Medical University of Vienna, Vienna BioCenter (VBC), Vienna, Austria.

Abstract

Abstract Cancer cells adapt and survive through the acquisition and selection of molecular modifications. This process defines cancer evolution. Building on a theoretical framework based on heritable genetic changes has provided insights into the mechanisms supporting cancer evolution. However, cancer hallmarks also emerge via heritable nongenetic mechanisms, including epigenetic and chromatin topological changes, and interactions between tumor cells and the tumor microenvironment. Recent findings on tumor evolutionary mechanisms draw a multifaceted picture where heterogeneous forces interact and influence each other while shaping tumor progression. A comprehensive characterization of the cancer evolutionary toolkit is required to improve personalized medicine and biomarker discovery. Significance: Tumor evolution is fueled by multiple enabling mechanisms. Importantly, genetic instability, epigenetic reprogramming, and interactions with the tumor microenvironment are neither alternative nor independent evolutionary mechanisms. As demonstrated by findings highlighted in this perspective, experimental and theoretical approaches must account for multiple evolutionary mechanisms and their interactions to ultimately understand, predict, and steer tumor evolution.

Funder

European Molecular Biology Organization

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3